Article
Novel 5α-reductase inhibitors unlinked to depression-like phenotypes in rat model of BPH.
The Journal of steroid biochemistry and molecular biology - 1 Sept 2026
Khanna Bhawna, Rana Priyanka, Saini Akash, Sah Sangeeta Pilkhwal, Dhingra Neelima
Abstract excerpt
Finasteride clinically approved for the treatment of benign prostatic hyperplasia exerts its therapeutic effect by inhibiting type II 5α-reductase, thereby reducing dihydrotestosterone levels, leading to prostate shrinkage and symptomatic relief. However, finasteride also influences the levels of neurosteroids (allopregnanolone) and has been linked to depression-like behavior and impaired neurogenesis....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
